IRLAB prepares for listing on the Nasdaq Stockholm main market

May 17, 2018

IRLAB Therapeutics AB’s board of directors has resolved to evaluate listing the company’s shares on Nasdaq Stockholm’s main market.

IRLAB Therapeutics AB’s board of directors has resolved to evaluate listing the company’s shares on Nasdaq Stockholm’s main market.

Since February 28, 2017, IRLAB’s shares trade on Nasdaq Stockholm First North Premier. The board considers that a listing on the main market will enhance the company’s development opportunity.

Documents & Links